199 related articles for article (PubMed ID: 26071757)
1. DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers.
Vaclová T; Gómez-López G; Setién F; Bueno JM; Macías JA; Barroso A; Urioste M; Esteller M; Benítez J; Osorio A
Breast Cancer Res Treat; 2015 Jul; 152(2):271-82. PubMed ID: 26071757
[TBL] [Abstract][Full Text] [Related]
2. Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.
Chehade R; Pettapiece-Phillips R; Salmena L; Kotlyar M; Jurisica I; Narod SA; Akbari MR; Kotsopoulos J
Breast Cancer Res; 2016 Aug; 18(1):87. PubMed ID: 27534398
[TBL] [Abstract][Full Text] [Related]
3. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
4. Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes.
Cochran RL; Cidado J; Kim M; Zabransky DJ; Croessmann S; Chu D; Wong HY; Beaver JA; Cravero K; Erlanger B; Parsons H; Heaphy CM; Meeker AK; Lauring J; Park BH
Oncotarget; 2015 Sep; 6(28):25240-51. PubMed ID: 26246475
[TBL] [Abstract][Full Text] [Related]
5. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T
Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570
[TBL] [Abstract][Full Text] [Related]
6. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
[TBL] [Abstract][Full Text] [Related]
7. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
[TBL] [Abstract][Full Text] [Related]
8. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
Alshareeda AT; Negm OH; Aleskandarany MA; Green AR; Nolan C; TigHhe PJ; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Aug; 159(1):41-53. PubMed ID: 27464795
[TBL] [Abstract][Full Text] [Related]
9. Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation.
Baert A; Depuydt J; Van Maerken T; Poppe B; Malfait F; Storm K; van den Ende J; Van Damme T; De Nobele S; Perletti G; De Leeneer K; Claes KB; Vral A
Breast Cancer Res; 2016 May; 18(1):52. PubMed ID: 27184744
[TBL] [Abstract][Full Text] [Related]
10. Fidelity of DNA double-strand break repair in heterozygous cell lines harbouring BRCA1 missense mutations.
Coupier I; Baldeyron C; Rousseau A; Mosseri V; Pages-Berhouet S; Caux-Moncoutier V; Papadopoulo D; Stoppa-Lyonnet D
Oncogene; 2004 Jan; 23(4):914-9. PubMed ID: 14647443
[TBL] [Abstract][Full Text] [Related]
11. Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
Vilasco M; Communal L; Hugon-Rodin J; Penault-Llorca F; Mourra N; Wu Z; Forgez P; Gompel A;
Breast Cancer Res Treat; 2013 Nov; 142(2):283-96. PubMed ID: 24166279
[TBL] [Abstract][Full Text] [Related]
12. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
13. iPSC-Derived Hereditary Breast Cancer Model Reveals the
Portier L; Desterke C; Chaker D; Oudrhiri N; Asgarova A; Dkhissi F; Turhan AG; Bennaceur-Griscelli A; Griscelli F
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513753
[TBL] [Abstract][Full Text] [Related]
14. Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency.
Rennstam K; Ringberg A; Cunliffe HE; Olsson H; Landberg G; Hedenfalk I
Genes Chromosomes Cancer; 2010 Jan; 49(1):78-90. PubMed ID: 19839046
[TBL] [Abstract][Full Text] [Related]
15. Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair.
Arnold K; Kim MK; Frerk K; Edler L; Savelyeva L; Schmezer P; Wiedemeyer R
Cancer Lett; 2006 Nov; 243(1):90-100. PubMed ID: 16448746
[TBL] [Abstract][Full Text] [Related]
16. Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
Jeng YM; Cai-Ng S; Li A; Furuta S; Chew H; Chen PL; Lee EY; Lee WH
Oncogene; 2007 Sep; 26(42):6160-6. PubMed ID: 17420720
[TBL] [Abstract][Full Text] [Related]
17. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
Armes JE; Trute L; White D; Southey MC; Hammet F; Tesoriero A; Hutchins AM; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
Cancer Res; 1999 Apr; 59(8):2011-7. PubMed ID: 10213514
[TBL] [Abstract][Full Text] [Related]
18. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
19. ABRAXAS1 orchestrates BRCA1 activities to counter genome destabilizing repair pathways-lessons from breast cancer patients.
Sachsenweger J; Jansche R; Merk T; Heitmeir B; Deniz M; Faust U; Roggia C; Tzschach A; Schroeder C; Riess A; Pospiech H; Peltoketo H; Pylkäs K; Winqvist R; Wiesmüller L
Cell Death Dis; 2023 May; 14(5):328. PubMed ID: 37198153
[TBL] [Abstract][Full Text] [Related]
20. Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families.
Rothfuss A; Schütz P; Bochum S; Volm T; Eberhardt E; Kreienberg R; Vogel W; Speit G
Cancer Res; 2000 Jan; 60(2):390-4. PubMed ID: 10667592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
